October 16, 2024 US Time --- BlissBio announced that its investigational new drug (IND) application of an innovative antibody-drug conjugate (ADC) BB-1712 was approved by the U.S. Food and Drug Administration (FDA). BB-1712, a B7-H3 targeted ADC with Eribulin as its toxin, is developed for the treatment of multiple solid tumors.
September 11, 2024 – BlissBio announces today the Phase II clinical data of antibody-drug conjugate (ADC) BB-1701 will be presented at the European Society for Medical Oncology (ESMO) Congress 2024, which will be held in Barcelona, Spain from September 13 to 17.
HANGZHOU, China, June 1, 2024 – BlissBio announces today the Phase I clinical data of Anti-tumor antibody-drug conjugate (ADC) BB-1701 will be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting 2024 from May 31 to June 4, 2024, in Chicago, IL, U.S..
HANGZHOU, June 06, 2023 --- Bliss Biopharmaceutical (Hangzhou) Co., Ltd. (“BlissBio”) announced the completion of Series B++ financing invested by Eisai Co., Ltd (“Eisai”).